BR112022000778A2 - Anticorpos anti-grp78 e método de uso dos mesmos - Google Patents

Anticorpos anti-grp78 e método de uso dos mesmos

Info

Publication number
BR112022000778A2
BR112022000778A2 BR112022000778A BR112022000778A BR112022000778A2 BR 112022000778 A2 BR112022000778 A2 BR 112022000778A2 BR 112022000778 A BR112022000778 A BR 112022000778A BR 112022000778 A BR112022000778 A BR 112022000778A BR 112022000778 A2 BR112022000778 A2 BR 112022000778A2
Authority
BR
Brazil
Prior art keywords
grp78
useful
antigen
binding proteins
tumor
Prior art date
Application number
BR112022000778A
Other languages
English (en)
Inventor
Kumar Singh Abhay
Dennis Hallahan
Vaishali Kapoor
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of BR112022000778A2 publication Critical patent/BR112022000778A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

anticorpos anti-grp78 e método de uso dos mesmos. a presente invenção se refere a anticorpos isolados que se ligam à grp78. especificamente, as composições que compreendem proteínas de ligação de antígeno anti-grp78 úteis no reconhecimento de células cancerosas ou tumorais. ademais, em alguns aspectos, as proteínas de ligação de antígeno anti-grp78 são úteis para entrega de fármacos e terapias específicos de tumor/câncer. em outro aspecto, as proteínas de ligação de antígeno reveladas são úteis para melhorar a radioterapia em um indivíduo que tem ou suspeito de ter câncer ou um tumor em que a proteína de ligação de antígeno é conjugada a uma carga útil, por exemplo, um agente terapêutico, um agente de imageamento ou uma combinação dos mesmos.
BR112022000778A 2019-07-16 2020-07-16 Anticorpos anti-grp78 e método de uso dos mesmos BR112022000778A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962874791P 2019-07-16 2019-07-16
PCT/US2020/042374 WO2021011798A1 (en) 2019-07-16 2020-07-16 Anti-grp78 antibodies and method of use thereof

Publications (1)

Publication Number Publication Date
BR112022000778A2 true BR112022000778A2 (pt) 2022-04-12

Family

ID=74211341

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022000778A BR112022000778A2 (pt) 2019-07-16 2020-07-16 Anticorpos anti-grp78 e método de uso dos mesmos

Country Status (15)

Country Link
US (1) US20220259322A1 (pt)
EP (1) EP3999547A4 (pt)
JP (1) JP2022541765A (pt)
KR (1) KR20220034823A (pt)
CN (1) CN114585647A (pt)
AU (1) AU2020314851A1 (pt)
BR (1) BR112022000778A2 (pt)
CA (1) CA3147606A1 (pt)
CL (1) CL2022000107A1 (pt)
CO (1) CO2022001643A2 (pt)
IL (1) IL289905A (pt)
MX (1) MX2022000671A (pt)
PE (1) PE20220646A1 (pt)
WO (1) WO2021011798A1 (pt)
ZA (1) ZA202201160B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115304680B (zh) * 2022-03-11 2024-02-02 四川大学华西医院 基于Pep42构建的双特异性细胞接合器分子的制备及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001245945A1 (en) * 2000-03-23 2001-10-03 Pe Corporation (Ny) Detection kits, such as nucleic acid arrays, for detecting the expression of 10,000 or more drosophila genes and uses thereof
US20080131451A1 (en) * 2004-03-05 2008-06-05 Giancarlo Tanzi Epitope escape mutations
MX2008000429A (es) * 2005-07-18 2008-03-10 Basf Plant Science Gmbh Aumento del rendimiento en plantas con sobreexpresion de los genes accdp.
WO2007064919A2 (en) * 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
WO2013019730A1 (en) * 2011-07-29 2013-02-07 The Washington University Antibodies to tip-1 and grp78
US9534044B2 (en) * 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
CN105452292A (zh) * 2013-03-14 2016-03-30 帕卡什·吉尔 使用结合细胞表面grp78的抗体进行癌症治疗
RU2733754C2 (ru) * 2015-05-20 2020-10-06 Те Брод Инститьют Инк. Общие неоантигены

Also Published As

Publication number Publication date
WO2021011798A1 (en) 2021-01-21
PE20220646A1 (es) 2022-04-28
JP2022541765A (ja) 2022-09-27
CL2022000107A1 (es) 2022-10-21
IL289905A (en) 2022-03-01
CA3147606A1 (en) 2021-01-21
US20220259322A1 (en) 2022-08-18
KR20220034823A (ko) 2022-03-18
ZA202201160B (en) 2022-09-28
AU2020314851A1 (en) 2022-02-10
CO2022001643A2 (es) 2022-05-31
CN114585647A (zh) 2022-06-03
EP3999547A4 (en) 2023-07-12
EP3999547A1 (en) 2022-05-25
MX2022000671A (es) 2022-04-18

Similar Documents

Publication Publication Date Title
CY1124791T1 (el) Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων
BR112019023754A2 (pt) anticorpo anti-sirpalpha ou um fragmento de ligação ao antígeno do mesmo, composição farmacêutica, e, combinação do anticorpo anti-sirpalpha ou da composição farmacêutica.
PH12019500270A1 (en) Combination therapy for cancer
BR112018070676A2 (pt) construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos
BR112018008806A2 (pt) peptídeos e combinações de peptídeos para uso na imunoterapia de diversos cânceres
BR112017017560A2 (pt) peptídeos e combinações de peptídeos para uso em imunoterapia do câncer de pulmão, incluindo cpcnp e outros câncere
BR112018001687A2 (pt) peptídeos e combinações de peptídeos para uso na imunoterapia contra o câncer de próstata e outros cânceres
BR112018075198A2 (pt) método para o tratamento de câncer ou uma doença associada a patógeno, composição farmacêutica, e kit
BR112018007046A2 (pt) anticorpo isolado ou fragmento de ligação a antígeno, composição farmacêutica, molécula de polinucleotídeo isolado, vetor, célula, e, métodos para inibir o crescimento de um tumor ou de uma célula tumoral e para tratar uma doença ou distúrbio.
ZA202005259B (en) Anti-ctla4 antibodies and methods of making and using the same
MX2019009967A (es) Moleculas de union biespecificas que son capaces de unirse a cd137 y a antigenos tumorales, y usos de las mismas.
BR112018003460A2 (pt) peptídeos, combinações de peptídeos e suportes para emprego na imunoterapia de diversos cânceres
BR112018015545A2 (pt) tratamentos de câncer do útero
BR112017017289A2 (pt) peptídeos e combinações de peptídeos para uso em imunoterapia contra diversos tumores
BR112017023362A2 (pt) peptídeos e combinação de peptídeos e arcabouços dos mesmos para uso na imunoterapia contra o carcinoma colorretal (crc) e outros cânceres
BR112017008972A2 (pt) peptídeos e combinações de peptídeos para uso em imunoterapia contra carcinoma hepatocelular (hcc) e outros cânceres
ZA201904218B (en) Anti¿ccr7 antibody drug conjugates
BR112021023229A2 (pt) Conjugados anticorpo-fármaco inibidores de mcl-1 e métodos de uso
BR112016020752A2 (pt) ?anticorpo isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, e, métodos para tratamento de um câncer ou tumor expressando egfrviii e para tratamento de um câncer, redução de crescimento de tumor e/ou causação de regressão de tumor em um paciente?
PE20210375A1 (es) Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales
BR112018075434A2 (pt) anticorpo isolado ou fragmento de ligação de antígeno do mesmo, composição farmacêutica, e, métodos para tratar câncer e para modular resposta imune antitumor.
BR112020016331A8 (pt) Métodos para tratar câncer com anticorpos anti-pd-1
WO2016123591A3 (en) Compositions and methods for treatment and detection of cancers
BR112017028363A2 (pt) peptídeos e combinações de peptídeos para uso na imunoterapia contra o câncer de esôfago e outros cânceres
BR112021009275A2 (pt) Anticorpo humanizado anti-sirp alfa ou um fragmento de ligação a antígeno do mesmo, composição farmacêutica, molécula de ácido nucleico, e, célula hospedeira.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]